By Peter Nurse Investing.com -- Stocks in focus in premarket trade on Tuesday, July 5th. Please refresh for updates. Tesla (NASDAQ:TSLA) stock fell 1.4% after the electric car manufacturer...
By Scott Kanowsky Investing.com -- AstraZeneca (NASDAQ:AZN) has announced that it plans to acquire U.S. oncology firm TeneoTwo in a deal worth up to $1.27B, as the British-based...
By Peter Nurse Investing.com - European stock markets edged lower Tuesday, with concerns about the region’s economic recovery diluting the positive start to the new month. By 04:20 AM ET...
(Reuters) – AstraZeneca said on Tuesday it will acquire oncology firm TeneoTwo Inc in a deal worth up to $1.27 billion, including the company’s initial stage T-cell engager.
Here's a roundup of top developments in the biotech space over the last 24 hours: Stocks In Focus FDA Expert Panel Favors COVID-19 Boosters Targeting Omicron BA.4, BA.5 Subvariants The FDA's...
SEOUL (Reuters) – South Korea on Thursday authorised AstraZeneca PLC’s antibody-based therapy for preventing COVID-19 infection in people with a poor immune response, increasing its...
(Reuters) – Drugmaker AstraZeneca said on Thursday its cancer drug Imfinzi, when given along with neoadjuvant chemotherapy in a late-stage trial, showed promise in helping patients with...
Investing.com – U.K. equities were lower at the close on Wednesday, as losses in the Automobiles & Parts, Real Estate Investment Trusts REITs and Real Estate sectors propelled shares...
2 mutations who have HER2-negative high-risk early breast cancer previously treated with neoadjuvant or adjuvant chemotherapy. Trastuzumab deruxtecan is a HER2-directed antibody-drug...
Here's a roundup of top developments in the biotech space over the last 24 hours: Stocks In Focus EMA's Advisory Committee Backs Approval For AstraZeneca's Targeted Breast Cancer...
Two cancer therapies from AstraZeneca (GB:AZN) have been approved for treating patients with breast cancer in the European Union. The move boosts the company’s oncology portfolio, with one...
The decision was based on trial results showing that Enhertu cut the risk of disease progression or death by 72% compared with the trastuzumab emtansine drug.
(Reuters) – AstraZeneca said on Monday its cancer drugs Lynparza, developed with Merck & Co and Enhertu, developed with Japan’s Daiichi Sankyo, were recommended for the treatment of some...
U.S.-listed shares of AstraZeneca were up 2.5% in trading on Tuesday after the company said an experimental therapy for hereditary transthyretin-mediated amyloid polyneuropathy met its...
Here's a roundup of top developments in the biotech space over the last 24 hours: Stocks In Focus FDA AdComm Gives Thumbs Down To Acadia's Pimavanserin A panel of the FDA's outside experts...
LONDON (Reuters) – An interim analysis of AstraZeneca and partner Ionis Pharmaceuticals’ eplontersen showed the experimental drug met the main goals in a late-stage trial in patients...
AstraZeneca is considering a bid for London-based, U.S.-listed biotech Mereo BioPharma , The Times reported without attribution. AstraZeneca already is a partner of Mereo, and the report...
A new study showed Enhertu cut the risk of tumor progression by half for people with the most advanced form of the disease, offering the prospect of a new treatment for one of the most...
AstraZeneca Plc (NASDAQ: AZN) and Daiichi Sankyo's (OTC: DSKYF) Enhertu extended survival by more than six months in patients with a form of advanced breast cancer compared to standard...
AstraZeneca (GB: AZN) (AZN) has released positive results associated with Enhertu (trastuzumab deruxtecan), the first-of-its-kind HER2 directed antibody-drug conjugate (ADC). It is jointly...
By Natalie Grover LONDON (Reuters) – AstraZeneca and Daiichi Sankyo’s Enhertu extended survival by more than six months in patients with a form of advanced breast cancer compared to...
Investing.com – U.K. equities were higher at the close on Wednesday, as gains in the Industrial Metals & Mining, Oil & Gas Producers and Life Insurance/Assurance sectors propelled shares...
Investing.com - AstraZeneca (LON:AZN) reported on Friday first quarter {{erl-6565||earnings that beat analysts' forecasts and revenue that topped expectations. AstraZeneca announced...
AstraZeneca (NASDAQ:AZN) reported Q1 EPS of $1.89, $1.06 better than the analyst estimate of $0.83. Revenue for the quarter came in at $11.4 billion versus the consensus estimate of $10.99...
Investing.com - AstraZeneca (LON:AZN) ADR reported first quarter {{erl-39111||earnings that beat analysts' expectations on Friday and revenue that topped forecasts. The firm reported...
By Laura Sanchez Investing.com - Today, investors focus on important macro data, such as eurozone inflation and GDP in different European countries. We will also keep an eye on the corporate...
Investing.com – U.K. equities were lower at the close on Thursday, as losses in the Automobiles & Parts, Household Goods & Home Construction and Life Insurance/Assurance sectors propelled...
Investing.com – U.K. equities were lower at the close on Monday, as losses in the Mining, Industrial Transportation and Fixed Line Telecommunications sectors propelled shares lower. At the...
Investing.com – U.K. equities were higher at the close on Tuesday, as gains in the Pharmaceuticals & Biotech, Automobiles & Parts and General Industrial sectors propelled shares higher. At...
Investing.com - AstraZeneca (LON:AZN) reported on Thursday fourth quarter {{erl-6565||earnings that beat analysts' forecasts and revenue that topped expectations. AstraZeneca announced...
Bringing vaccine manufacturing closer to Africa to speed up supply is important for building capacity in the region. Guerchom Ndebo/Getty ImagesSub-Saharan Africa still has too few vaccines...
By Gina Lee Investing.com – Asia Pacific stocks were mostly down on Monday morning, while U.S. futures were down, as bets that the U.S. Federal Reserve will hike interest rates also weighed...
US jobsIn the week ending Jan 8, the advance figure for seasonally adjusted initial claims was 230 000, an increase of 23 000 from the previous week's unrevised level of 207 000. The 4-week...
By Lewis Krauskopf, Medha Singh and Bansari Mayur Kamdar (Reuters) - Wall Street's main indexes posted solid gains for a third straight session on Thursday, with the S&P 500 marking a...
By Stephanie Kelly NEW YORK (Reuters) -Oil prices rose around 2% on Thursday, as record U.S. implied demand, falling crude stockpiles and an upbeat economic outlook from the Federal Reserve...
Disclaimer: Fusion Media would like to remind you that the data contained in this website is not necessarily real-time nor accurate. All CFDs (stocks, indexes, futures), cryptocurrencies, and Forex prices are not provided by exchanges but rather by market makers, and so prices may not be accurate and may differ from the actual market price, meaning prices are indicative and not appropriate for trading purposes. Therefore Fusion Media doesn't bear any responsibility for any trading losses you might incur as a result of using this data. Fusion Media or anyone involved with Fusion Media will not accept any liability for loss or damage as a result of reliance on the information including data, quotes, charts and buy/sell signals contained within this website. Please be fully informed regarding the risks and costs associated with trading the financial markets, it is one of the riskiest investment forms possible.
